Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604351 | 1.00 | PTGS2 (0.63) | PTGS2MAPTLMNATHRBSMN1; SMN2 | |
| SCHEMBL3610471 | 0.93 | PTGS2 (0.67) | PTGS2MAPTLMNATHRBSMN1; SMN2 | |
| SCHEMBL3610473 | 0.93 | PTGS2 (0.67) | PTGS2MAPTLMNATHRBSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3602182 | 0.93 | PTGS2 (0.56) | PTGS2MAPTLMNATHRBSMN1; SMN2 | |
| SCHEMBL3609809 | 0.88 | ADORA1 (0.53) | PTGS2MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3602954 | 0.88 | ADORA1 (0.53) | PTGS2MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3602952 | 0.88 | ADORA1 (0.53) | PTGS2MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3613688 | 0.83 | MAOA (0.56) | PTGS2MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3615614 | 0.83 | MAOA (0.56) | PTGS2MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3613693 | 0.83 | MAOA (0.56) | PTGS2MAPTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | PTGS2 356/4885MAPT 3376/4885LMNA 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.